Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) EPS (Weighted Average and Diluted) (2020 - 2025)

Acro Biomedical has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at $0.0 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $0.0 for Q4 2025, up 498.44% from a year ago — trailing twelve months through Dec 2025 was -$0.0 (down 139.13% YoY), and the annual figure for FY2025 was -$0.0, down 139.13%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.0 at Acro Biomedical, up from -$0.0 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for ACBM hit a ceiling of $0.04 in Q4 2021 and a floor of -$0.07 in Q3 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.0 (2025), compared with a mean of -$0.02.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 3299.02% in 2021 and later plummeted 1051.72% in 2025.
  • Acro Biomedical's EPS (Weighted Average and Diluted) stood at $0.04 in 2021, then tumbled by 245.02% to -$0.06 in 2022, then skyrocketed by 99.49% to -$0.0 in 2023, then surged by 41.49% to -$0.0 in 2024, then surged by 498.44% to $0.0 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $0.0 (Q4 2025), -$0.0 (Q3 2025), and -$0.0 (Q2 2025) per Business Quant data.